- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 319 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 304 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 350 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 06.11.25 | Rani Therapeutics announces $1.085 billion Chugai collaboration | 15 | Investing.com | ||
| 27.10.25 | Chugai acquires Renalys, enhancing its kidney disease portfolio | 3 | Pharmaceutical Technology | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 24.10.25 | Chugai buys a kidney biotech; ICER targets rising launch prices | 4 | BioPharma Dive | ||
| 24.10.25 | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | 29 | FiercePharma | ||
| 24.10.25 | Chugai buys 'Asia lag' firm Renalys for $98m upfront | 3 | pharmaphorum | ||
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 369 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 23.10.25 | Roche axes 4 Chugai solid tumor assets in early-phase clearout | 10 | FierceBiotech | ||
| 17.10.25 | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | 12 | FierceBiotech | ||
| 17.10.25 | Rani Therapeutics surges on Chugai licensing deal, private placement | 32 | Seeking Alpha | ||
| 17.10.25 | Rani Therapeutics: Aktie schießt nach potenziellem Milliarden-Deal mit Chugai in die Höhe | 37 | Investing.com Deutsch | ||
| 17.10.25 | Rani Therapeutics stock soars after inking $1 billion potential deal with Chugai | 11 | Investing.com | ||
| 17.10.25 | Rani Therapeutics signs $1 billion potential deal with Chugai for oral biologics | 4 | Investing.com | ||
| 17.10.25 | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 560 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| 27.08.25 | Chugai spikes after Eli Lilly trial win for obesity pill | 23 | Seeking Alpha | ||
| 08.08.25 | Chugai stock drops the most since 1977 on disappointing obesity drug data | 32 | Japan Times | ||
| 24.07.25 | Chugai Pharmaceutical reports Q2 results | 9 | Seeking Alpha | ||
| 19.06.25 | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | 789 | JCN Newswire | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 7,115 | +2,52 % | TRULIEVE CANNABIS CORP: Struktur in der Ruhephase | ||
| WEST PHARMACEUTICAL SERVICES | 243,00 | +1,12 % | West Pharmaceutical Services - Wachstum des Marktes für Abnehmspritzen und andere Faktoren beflügeln das Geschäft | ||
| SHIONOGI | 15,700 | +1,95 % | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| KALA BIO | 0,575 | +0,09 % | KALA BIO, Inc. - 8-K, Current Report | ||
| CHARLOTTES WEB | 0,280 | -8,50 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results |
Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,480 | 0,00 % | AIM - Suspension - Beximco Pharmaceuticals PLC | ||
| LUYE PHARMA | 0,318 | +3,92 % | LUYE PHARMA (02186): TERMS OF REFERENCE FOR NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS OF THE COMPANY | ||
| MIRUM PHARMACEUTICALS | 66,00 | +0,76 % | Mirum Pharmaceuticals auf Rekordhoch: Aktie steigt auf 82,65 USD | ||
| PERCHERON THERAPEUTICS | 0,007 | +18,18 % | Edison Group: Edison Issues Report on Percheron Therapeutics (PER) | London, United Kingdom--(Newsfile Corp. - November 27, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)We have refreshed our investment case for Percheron as the company heads into... ► Artikel lesen | |
| AYURCANN | 0,005 | 0,00 % | Ayurcann Holdings Corp.: Ayurcann Reports Q1 2026 Sales Of $14,638,697 | Toronto, Ontario, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) ("Ayurcann" or the "Company") is excited to announce its financial and operational results for... ► Artikel lesen | |
| AVANT BRANDS | 0,530 | 0,00 % | Avant Brands Inc.: Avant Brands Fully Repays $9.5M Secured Convertible Debenture | KELOWNA, BC / ACCESS Newswire / December 8, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products... ► Artikel lesen | |
| KALBE FARMA | 0,056 | 0,00 % | KLBF to buyback shares, allocating IDR 250 billion: KLBF plans to repurchase shares worth IDR 250 billion over ... | ||
| EVEREST MEDICINES | 4,060 | -7,31 % | Everest Medicines Limited: Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares | HONG KONG, Dec 15, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company's shares strengthened during the trading session... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 29,000 | +0,69 % | Dividendenbekanntmachungen (29.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| SILO WELLNESS | 0,008 | -100,00 % | Silo Wellness Inc.: Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business | Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,600 (-2,70 %) liegt der Kurs bei 21,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.